5,059 research outputs found
Variations on the Author
No full text“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
FRAGMATIC: A randomised phase III clinical trial investigating the effect of <b>fragm</b>in<sup>® </sup><b>a</b>dded to standard <b>t</b>herapy <b>i</b>n patients with lung <b>c</b>ancer
No full textAbstract Background Venous thromboembolism (VTE) occurs when blood clots in the leg, pelvic or other deep vein (deep vein thrombosis) with or without transport of the thrombus into the pulmonary arterial circulation (pulmonary embolus). VTE is common in patients with cancer and is increased by surgery, chemotherapy, radiotherapy and disease progression. Low molecular weight heparin (LMWH) is routinely used to treat VTE and some evidence suggests that LMWH may also have an anticancer effect, by reduction in the incidence of metastases. The FRAGMATIC trial will assess the effect of adding dalteparin (FRAGMIN), a type of LMWH, to standard treatment for patients with lung cancer. Methods/Design The study design is a randomised multicentre phase III trial comparing standard treatment and standard treatment plus daily LMWH for 24 weeks in patients with lung cancer. Patients eligible for this study must have histopathological or cytological diagnosis of primary bronchial carcinoma (small cell or non-small cell) within 6 weeks of randomisation, be 18 or older, and must be willing and able to self-administer 5000 IU dalteparin by daily subcutaneous injection or have it administered to themselves or by a carer for 24 weeks. A total of 2200 patients will be recruited from all over the UK over a 3 year period and followed up for a minimum of 1 year after randomisation. Patients will be randomised to one of the two treatment groups in a 1:1 ratio, standard treatment or standard treatment plus dalteparin. The primary outcome measure of the trial is overall survival. The secondary outcome measures include venous thrombotic event (VTE) free survival, serious adverse events (SAEs), metastasis-free survival, toxicity, quality of life (QoL), levels of breathlessness, anxiety and depression, cost effectiveness and cost utility. Trial registration Current Controlled Trials ISRCTN80812769</p
Interim safety data on the FRAGMATIC trial: a randomised phase III clinical trial investigating the effect of FRAGMin (R) added to standard therapy in patients with lung cancer
No full textBackground: Venous thromboembolism (VTE) is common in lungcancer patients and the incidence is increased by treatments. Lungcancer patients often have advanced disease at presentation, as wellas co-morbidities, such as heart failure and chronic lung disease allof which increase the risk of VTE. Low molecular weight heparin(LMWH) has been used in the prophylaxis of VTE but there arelimited data on the use of LMWH as primary thromboprophylaxisin cancer patients. Because of this and interesting animal data suggestingthat LMWH may be anti-metastatic, the effect of long termLMWH on overall survival should be investigated
State of Utah v. Timothy Craig Godfrey : Brief of Appellant
No full textAppeal following the entrance of a conditional guilty plea resulting in judgment and conviction for Unlawful Possession of a Controlled Substance, a third degree felony, in violation of Utah Code Ann. § 58-37-8, wherein Timothy Craig Godfrey seeks reversal of the trial court\u27s denial of two pre-trial motions decided by the Honorable Paul G. Maughan, Judge, Third Judicial District Court in and for Salt Lake County, State of Utah
Timothy Meyer serves as a contributing author for UN report
No full textAssistant Professor Timothy Meyer served as a contributing author for the United Nations Industrial Development Organization\u27s report titled Networks for Prosperity: Connecting Development Knowledge Beyond 2015. The document, which was released during November, analyzes the nexus between the global connectedness of a country and its economic success, sustainability and government effectiveness. Meyer was one of only approximately 20 academic and practical experts from around the world selected to serve as a contributor after a global call for proposals.
Learn more View the full repor
Five minutes with Timothy Gowers: “academics can publish journals of the highest quality without a commercial entity”
No full textFields Medal-winning Cambridge mathematician Sir Timothy Gowers and a team of colleagues have recently launched a new editor-owned Open Access (OA) journal for mathematics. Discrete Analysis is an arXiv overlay journal, which means articles are submitted and hosted via the preprint server arXiv first. The journal coordinates peer-review and publishes via Scholastica with no cost to reader or author. Gowers reflects here on his vision for the future of editor-owned journals
The Baptismal Liturgy of Theodore of Mopsuestia
No full textTimothy A. Curtin.Typescript.Thesis (S.T.D.)--Catholic University of America, 1971.Bibliography: leaves 368-393
sj-pdf-2-ctj-10.1177_17407745211069879 – Supplemental material for Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer
No full textSupplemental material, sj-pdf-2-ctj-10.1177_17407745211069879 for Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer by Louise C Brown, Janet Graham, David Fisher, Richard Adams, Jenny Seligmann, Matthew Seymour, Richard Kaplan, Emma Yates, Mahesh Parmar, Susan D Richman, Philip Quirke, Rachel Butler, Kaikeen Shiu, Gary Middleton, Leslie Samuel, Richard H Wilson and Timothy S Maughan in Clinical Trials</p
sj-docx-1-ctj-10.1177_17407745211069879 – Supplemental material for Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer
No full textSupplemental material, sj-docx-1-ctj-10.1177_17407745211069879 for Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer by Louise C Brown, Janet Graham, David Fisher, Richard Adams, Jenny Seligmann, Matthew Seymour, Richard Kaplan, Emma Yates, Mahesh Parmar, Susan D Richman, Philip Quirke, Rachel Butler, Kaikeen Shiu, Gary Middleton, Leslie Samuel, Richard H Wilson and Timothy S Maughan in Clinical Trials</p
Practical Equality: Discussion with Author Robert L. Tsai
No full textProfessor Timothy Zick discusses a new book titled Practical Equality: Forging Justice in a Divided Nation, with its author, Professor Robert L. Tsai of American University Washington College of Law. Timothy Zick is the John Marshall Professor of Government and Citizenship at William & Mary Law School. His scholarship has explored a wide variety of constitutional issues, with a special focus on the First Amendment. Robert L. Tsai is Professor of Law at American University and a prize-winning essayist in constitutional law and history. Recorded before a live audience at William & Mary Law School on March 14, 2019. The event was sponsored by the American Constitution Society. Professor Tsai was also a panelist during the annual Bill of Rights Journal Symposium on March 15 & 16, 2019
- …
